menu
    • menu
    [{"orgOrder":0,"company":"Walgreens","sponsor":"Prothena","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Collaboration","leadProduct":"PRX012","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I","graph3":"Walgreens","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Walgreens \/ Prothena","highestDevelopmentStatusID":"6","companyTruncated":"Walgreens \/ Prothena"},{"orgOrder":0,"company":"Walgreens","sponsor":"Walgreens","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Dietary Supplement","year":"2011","type":"Inapplicable","leadProduct":"Fish Oil","moa":"Diacylglycerol O-acyltransferase 2; Prostaglandin G\/H synthase 2; Free fatty acid receptor 4; Voltage gated L-type calcium channel; Sodium channel protein; Free radicals; Nuclear factor NF-kappa-B; Sterol regulatory element-binding protein 1; Peroxisome proliferator-activated receptor alpha; Peroxisome proliferator-activated receptor gamma; Peroxisome proliferator-activated receptor delta","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Walgreens","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Walgreens \/ Walgreens","highestDevelopmentStatusID":"1","companyTruncated":"Walgreens \/ Walgreens"}]

    Find Clinical Drug Pipeline Developments & Deals by Walgreens

    Menu

    Walgreens

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Walgreens

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Walgreens

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PRX012

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Prothena

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Walgreens and Prothena Partner to Increase Access and Enrollment in Alzheimer’s Disease Clinical Trial

                            Details : The collaboration aims to accelerate patient identification and recruitment for Prothena’s ASCENT-2 clinical trial evaluating the safety and tolerability of PRX012, a potential best-in-class anti-amyloid beta antibody under development for the treatmen...

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Undisclosed

                            April 13, 2023

                            Lead Product(s) : PRX012

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Prothena

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Walgreens

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Walgreens

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fish Oil

                            Therapeutic Area : Undisclosed

                            Study Phase : Undisclosed

                            Recipient : University of Mississippi, Oxford

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Method of Fish Oil Administration on Patient Compliance

                            Details : Fish Oil is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Dietary Supplement

                            Upfront Cash : Inapplicable

                            November 16, 2011

                            Lead Product(s) : Fish Oil

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Undisclosed

                            Recipient : University of Mississippi, Oxford

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth